Generic Name and Formulations:
Enalapril maleate, hydrochlorothiazide; 10mg/25mg; tabs.
Valeant Pharmaceuticals, Inc
Indications for VASERETIC:
Hypertension (not for initial therapy).
Switching from monotherapy with either component: start with Vaseretic 10/25 once daily, then adjust; max 20mg enalapril/day and 50mg HCTZ/day. Allow 2–3 weeks for titration of HCTZ component. Or, substitute for individually titrated components.
History of ACEI-associated or other angioedema. Anuria. Sulfonamide allergy. Concomitant neprilysin inhibitors (eg, sacubitril); do not administer lisinopril within 36hrs of switching to or from sacubitril/valsartan. Concomitant aliskiren in patients with diabetes.
Fetal toxicity may develop; discontinue if pregnancy is detected. Severe renal impairment. Salt/volume depletion. Severe CHF. Ischemic disease. Cerebrovascular disease. Renal artery stenosis. Dialysis (esp. high-flux membrane). Surgery. Diabetes. Gout. Asthma. SLE. Acute myopia. Secondary angle-closure glaucoma. Postsympathectomy. Monitor WBCs in renal or collagen vascular disease. Discontinue if angioedema, laryngeal edema, jaundice, or marked elevations in hepatic enzymes develop. Monitor BP, electrolytes, and renal function. Black patients may have higher rate of angioedema than non-Black patients. Elderly. Neonates. Pregnancy, nursing mothers: not recommended.
ACE inhibitor + diuretic (thiazide).
See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). May cause hyperkalemia with K+-sparing diuretics, K+ supplements, or K+ -containing salt substitutes. Hypokalemia with corticosteroids, ACTH. May increase digitalis, lithium toxicity. Increased risk of angioedema with concomitant mTOR inhibitors (eg, temsirolimus, sirolimus, everolimus) or neprilysin inhibitors. Nitritoid reactions with concomitant injectable gold (eg, sodium aurothiomalate); rare. Alcohol, CNS depressants may increase orthostatic hypotension. Adjust antidiabetic, antigout medications. Potentiates nondepolarizing muscle relaxants. Antagonizes norepinephrine. Potentiated by, and hypotension with diuretics, other antihypertensives. May be antagonized by, and renal toxicity potentiated by NSAIDs, including COX-2 inhibitors (monitor renal function periodically in elderly and/or volume-depleted). Decreased absorption with cholestyramine, colestipol resins. May interfere with parathyroid tests.
Cough, dizziness, headache, fatigue, myalgia, nausea, asthenia, orthostatic hypotension, diarrhea, angioedema, fluid or electrolyte imbalance, impotence, hyperuricemia, renal impairment, arrhythmias, increased cholesterol and triglycerides; rare; hepatic failure.
Renal (primarily), fecal.
Sign Up for Free e-newsletters
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- The Caregivers' Cancer Journey
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
- Survey of ACEP Councilors Reveals NP, PA Staffing Models, Practice Patterns Vary
- Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer
- Genetic Susceptibility to Pancreatic Cancer Linked to 6 Specific Gene Mutations
- Dinner Hour and Sleep Habits Affect Risk of Breast, Prostate Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|